+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 12 Actively Recruiting clinical trials

E

Actively Recruiting

This research aims to evaluate the effects of elafibranor in adults diagnosed with Primary Biliary Cholangitis PBC who also have cirrhosis, a condition where the liver develops scarring. PBC is a slowly worsening disease that damages bile ducts in the liver, causing bile acids to build up and further harm the liver. The study focuses on whether elafibranor can better prevent worsening clinical outcomes, such as disease progression leading to liver transplant or death, compared to a placebo. It also assesses the long-term safety of elafibranor and its impact on symptoms like itching and fatigue. Participants are randomly assigned to one of two groups one group takes an 80 mg tablet of elafibranor daily, and the other takes a placebo tablet that looks the same. The tablets are taken orally each morning with or without food. This double-blind study lasts up to 3.5 years for each participant, during which the effects and safety of the study drug are closely monitored. Throughout the study, participants undergo regular assessments including physical exams, vital signs checks, blood tests, liver imaging, and questionnaires about symptoms and quality of life. These evaluations happen at baseline, then every 6 to 12 months up to the end of treatment. Researchers measure various health indicators such as liver enzyme levels, bilirubin, liver stiffness, and symptom scores. Safety is monitored by tracking adverse events and changes in laboratory and clinical findings. The primary outcome is the time participants remain free from clinical events related to disease worsening over the study period.

Age: 18Years +All GendersPhase 3
198 locations
E

Actively Recruiting

Researchers are studying the effects of prasinezumab, given as an intravenous infusion, in people aged 50 to 85 with early-stage Parkinsons disease who are already receiving stable levodopa treatment. The study aims to compare prasinezumab to a placebo to evaluate its safety, how the body processes the drug, and its impact on motor symptoms related to Parkinsons disease. Participants will be randomly assigned to receive either prasinezumab or a placebo through IV infusions during the double-blind treatment phase. After this phase, eligible participants can join an open-label extension where they receive prasinezumab. The study follows participants for at least 104 weeks, with infusions and assessments scheduled throughout this period. During the study, participants will have regular visits for motor function assessments using the Movement Disorder Society Unified Parkinsons Disease Rating Scale MDS-UPDRS and other measures. Researchers will monitor adverse events, infusion reactions, and the presence of antibodies against prasinezumab. Blood samples will be taken at multiple time points to measure drug levels and immune responses. The total study duration extends through 2031, including safety follow-up after the last dose.

Age: 50Years - 85YearsAll GendersPhase 3
192 locations
E

Actively Recruiting

Autosomal Dominant Polycystic Kidney Disease ADPKD is a common genetic kidney condition where fluid-filled cysts develop in the kidneys. This Phase 2 study is evaluating the safety and effectiveness of an investigational drug called ABBV-CLS-628 for adults with ADPKD. The trial aims to understand how this treatment affects kidney volume and kidney function compared to placebo. Participants are randomly assigned to one of four groups three receive different doses of ABBV-CLS-628, and one receives a placebo. Each participant gets an intravenous infusion every 4 weeks for 92 weeks. After this treatment period, participants will be followed for up to 15 additional weeks to monitor their health and any effects. During the study, participants will attend regular visits to a hospital or clinic. Researchers will perform medical assessments, blood tests, and monitor for side effects. Questionnaires will also be completed to gather information. The main outcomes measured include changes in total kidney volume and kidney function, as well as tracking any adverse events over about 118 weeks total.

Age: 18Years - 55YearsAll GendersPhase 2
91 locations
C

Actively Recruiting

Healthy Volunteer

Cesarean section is a common surgical procedure worldwide, and managing acute postoperative pain effectively is crucial in obstetric anesthesiology. Researchers are evaluating whether intrathecal morphine provides better pain relief after elective cesarean delivery compared to the standard epidural morphine. This randomized clinical trial aims to clarify the optimal opioid administration route to support faster maternal recovery, newborn care, and safe breastfeeding. Pregnant women undergoing elective cesarean section will be randomly assigned to receive either intrathecal morphine at a dose of 80 mcg or epidural morphine given as a 2.5 mg bolus at the end of surgery, followed by another 2.5 mg bolus 24 hours later. The study focuses on comparing the effectiveness of these two analgesia methods during the first 24 hours after surgery. Participants will be monitored for pain levels during the first 24 and 48 hours after surgery, need for additional pain medication, sedation levels, nausea, vomiting, itching, impact of pain on movement and activities, and overall satisfaction with pain management. All evaluations will assess safety and comfort during recovery, with the primary outcome being pain control at 24 hours post-cesarean. The trial is conducted at Hospital Central do Funchal and lasts through the initial postoperative period.

Age: 18Years +FEMALEPhase 4
1 location
E

Actively Recruiting

Researchers are evaluating a combination of oral decitabine and ivosidenib as a first-line treatment for adults with newly diagnosed acute myeloid leukemia AML who have an IDH1 R132 mutation. This study focuses on older adults aged 60 years and above, or adults aged 18 years and older with specific health conditions that make them unsuitable for standard intensive chemotherapy. The main goals are to assess the rates of complete remission and incomplete marrow recovery, as well as to monitor the occurrence and severity of any adverse events. Participants will receive treatment cycles lasting 28 days, consisting of oral ivosidenib taken daily for 28 days and oral decitabine-cedazuridine tablets taken once daily for the first 5 days of each cycle. During screening and the first two treatment cycles, hydroxyurea or cytarabine may be used to control high white blood cell counts. Those who achieve remission may be eligible for allogeneic stem cell transplantation, after which they can resume ivosidenib treatment from day 60 post-transplant, continuing for up to two years. Throughout the study, participants will have regular assessments to monitor their response to treatment, including disease progression and any side effects. Those undergoing transplant will have additional evaluations before and after the procedure, including minimal residual disease statistics. The researchers will measure remission rates over three years, along with overall survival, event-free survival, quality of remission, and early mortality. Participants are followed until disease progression, unacceptable toxicity, withdrawal, or study completion, expected by April 2029.

Age: 18Years +All GendersPhase 2
20 locations
P

Actively Recruiting

This registry study focuses on adults with severe, symptomatic aortic stenosis who require valve replacement. It aims to evaluate how the Medtronic Evolut FX transcatheter aortic valve implantation TAVI System performs in these patients. The study seeks to determine whether using a standardized procedure for implanting the valve can improve safety and efficiency, and it will look at patient outcomes both shortly after the procedure and up to one year later. Participants will undergo the TAVI procedure with the Medtronic Evolut FX system as part of their usual medical care. The study will follow their progress during the hospital stay, at 30 days, and at one year after the procedure. This follow-up will assess heart health, valve function, and recovery, collecting data on complications, the need for pacemakers, and other relevant clinical outcomes. People taking part will have their health monitored through hospital visits and evaluations at specific time points. The main outcome is technical success immediately after the valve implantation. Researchers will also measure several important health events such as pacemaker implantation rates, hospital stay length, mortality, stroke, bleeding, kidney injury, and valve function at 30 days and one year. The study plans to enroll 500 participants across 12 hospitals in Portugal, with monitoring continuing until study completion in April 2028.

Age: 18Years +All Genders
12 locations
O

Actively Recruiting

Researchers are evaluating recovery outcomes in patients undergoing minimally invasive colorectal surgery, comparing standard laparoscopy and robot-assisted laparoscopy. This prospective, single-centre observational cohort study focuses on the patients perspective using the Quality of Recovery-15 QoR-15 questionnaire to measure recovery quality 24 hours after surgery. The study aims to capture anesthesia-specific variables to adjust for confounding factors and provide a comprehensive comparison between the two surgical approaches. Participants will undergo either robotic or laparoscopic colorectal resection as determined by the operating surgeon, following an Enhanced Recovery After Surgery ERAS protocol. The anesthetist will enroll patients and collect detailed preoperative, intraoperative, and postoperative data. Statistical methods including propensity-score matching and multivariable regression will be used to adjust for confounding and surgeon effects. During the study, participants will complete the QoR-15 questionnaire at 24 hours post-surgery, with additional assessments at post-anesthesia care unit discharge and 48 hours. Researchers will also monitor pain scores, opioid use, postoperative nausea and vomiting, time spent in recovery and operating rooms, intraoperative hemodynamic events, hospital length of stay, complications, and 30-day readmission rates. Detailed anesthesia management and surgical details will be recorded. Participation will last from enrollment before surgery through 30 days after surgery for follow-up and data collection.

Age: 18Years +All GendersPhase Not Applicable
1 location
S

Actively Recruiting

Researchers are evaluating the combination of sacituzumab tirumotecan and pembrolizumab compared to pembrolizumab alone in treating people with metastatic non-small cell lung cancer NSCLC who have high levels of PD-L1 expression at least 50%. The study aims to see whether adding sacituzumab tirumotecan improves overall survival compared to pembrolizumab alone. This is a phase 3, randomized, open-label trial sponsored by Merck Sharp & Dohme LLC. Participants are randomly assigned to receive either sacituzumab tirumotecan plus pembrolizumab or pembrolizumab alone. Sacituzumab tirumotecan is given by intravenous infusion on Days 1, 15, and 29 of each 6-week cycle, while pembrolizumab is administered by intravenous infusion on Day 1 of each 6-week cycle for up to 18 cycles. Supportive medications such as diphenhydramine, an H2 antagonist, acetaminophen, and dexamethasone are given around the first four infusions of sacituzumab tirumotecan to help manage infusion reactions. During the study, participants undergo assessments including overall survival, progression-free survival, response rates, and quality of life measured by validated questionnaires. Safety is monitored throughout the treatment period and beyond. The study tracks symptoms like cough, chest pain, and breathing difficulties, along with adverse events and treatment discontinuations. The total follow-up for outcomes may extend up to approximately 77 months, allowing for long-term monitoring of treatment effects and safety.

Age: 18Years +All GendersPhase 3
220 locations
E

Actively Recruiting

Researchers are evaluating the safety and effectiveness of intravenous thrombolysis IVT in adults who have had an acute ischemic stroke AIS and recently taken direct oral anticoagulants DOACs within the last 48 hours. This international, multicenter, randomized study aims to determine whether IVT combined with standard medical care leads to better outcomes at 90 days compared to standard care alone. The trial is designed as a phase 4 superiority study enrolling 906 participants at several high-volume stroke centers worldwide. Participants will be randomly assigned to one of two groups one group will receive intravenous thrombolysis using Tenecteplase or Alteplase along with the best standard medical treatment, while the other group will receive only the standard of care as per local and international guidelines. Treatment must begin within specific time windows based on stroke onset or MRI findings. The study follows current guidelines from major stroke organizations, ensuring participants receive appropriate care. During the study, participants will be monitored and assessed using the Modified Rankin Scale at 90 days to evaluate functional outcomes. Additional measures include stroke severity changes assessed by the NIH Stroke Scale within 24 hours, and quality of life questionnaires at 90 days. The study includes careful safety monitoring and long-term follow-up to fully assess treatment effects and participant well-being throughout and after the 90-day period.

Age: 18Years +All GendersPhase 4
109 locations
P

Actively Recruiting

Researchers are evaluating fazirsiran, an investigational drug, to see if it can reduce liver scarring fibrosis and slow disease progression in people with liver disease caused by an abnormal alpha-1 antitrypsin protein. The study compares fazirsiran to a placebo and aims to understand how the drug affects the body, including its impact on liver inflammation and abnormal protein levels. Liver biopsies will be taken twice to assess changes in liver scarring. Participants will receive either fazirsiran or a placebo through subcutaneous injections. The dosing schedule includes an injection on Day 1, at Week 4, and then every 12 weeks up to Week 196. The study is randomized and double-blind, meaning neither participants nor researchers know who receives the drug or placebo during the treatment period. During the study, participants will undergo liver biopsies and various assessments including imaging techniques and blood tests to monitor liver function, protein levels, liver stiffness, and inflammation. Researchers will also track side effects, lung function, vital signs, and laboratory results from the start of treatment through up to Week 230. The main focus is on measuring changes in liver fibrosis after 106 weeks, with ongoing safety and efficacy evaluations throughout the study.

Age: 18Years - 75YearsAll GendersPhase 3
89 locations

1-10 of 12

1